Clinical Trial Update: Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation [Phase 4]

View source ↗

Summary

Phase 4 trial investigating atomoxetine with cognitive remediation for cognition in schizophrenia completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognition in Schizophrenia
• Schizophrenia

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Cognition in Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2020-09-25